Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Theravance Biopharma is most often covered alongside Aardvark Therapeutics, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Theravance Biopharma is most often covered alongside Aardvark Therapeutics, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. Theravance Biopharma appears in 1 tracked Healthcare story from March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Theravance Biopharma. Shared-story counts are live from our verified record — not editorial picks.
The biotech sector saw a week of stark contrasts as Ascendis Pharma secured a critical FDA approval for its lead candidate, while Theravance Biopharma announced significant workforce reductions. Meanwhile, Aardvark Therapeutics faced a clinical setback with its HERO trial, and Esperion Therapeutics signaled a major shift in capital allocation.
Source: finanznachrichten.de · rttnews.com
Theravance Biopharma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
